In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A). The gene discussed is ERBB2; the disease is breast carcinoma.